TVM Capital Life Science, which is based in Munich and Montreal, said it raised the money from several high-profile international investors including Eli Lilly, which is working on a possible coronavirus treatment with Vancouver’s AbCellera and other partners, as well as other sources including strategic investors and pension funds. (The Logic)
Talking point: TVM said between 50 and 60 per cent of the fund’s capital will be invested in project-focused companies in which the fund has a majority stake, and remaining funds will be used to invest in late-clinical-stage biopharmaceutical companies, and commercial-stage medical-device and -diagnostic companies. The firm has made 55 investments, mostly in health technology, according to PitchBook. Its latest deal came in June, when it invested nearly $15 million in Emovi, a Montreal-based developer of a knee-assessment device.